About the Editors

Editors-in-Chief

Gerry Melino 

Gerry Melino, MD (Rome), PhD (London), Dr Sci hc (St Petersburg), working at the MRC Toxicology Unit (Leicester UK) and at the University Tor Vergata of Rome (Italy), has created the major forum for discussion and innovation in the field of cell death in the last twenty years. In fact, his editorial contribution to the scientific community has been pivotal, being the Founder & Editor-in-Chief of the journals Cell Death Differentiation (8.339), Cell Death Disease (5.965), and Cell Death Discovery. His scientific interest focuses upon programmed cell death in epidermal and cancer models, and in particular on the p53 family - p63 and p73, where his contribution has been fundamental.

 

Eric H Baehrecke

Eric Baehrecke obtained his Ph.D. from the University of Wisconsin – Madison, and was a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation at the University of Utah during his postdoctoral studies. He was a faculty member of the University of Maryland from 1995-2007, and is currently a Professor in the Department of Molecular, Cell and Cancer Biology at the University of Massachusetts Medical School. His team studies the regulation and function of autophagy in cell survival and cell death, and the mechanisms controlling non-apoptotic cell death.

Deputy Editors

Guido Kroemer

Guido Kroemer currently serves as a Research Director at INSERM, in the INSERM Unit 848, located in Villejuif, France. Prior to joining the INSERM (1993), he was Senior Scientist of the European Community at the Spanish National Research Council (CSIC) at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). He did his postdoctoral training in the Collège de France, Nogent-sur-Marne, France (1988-1989) and at the University of Innsbruck, Austria, after receiving his PhD and MD degrees at the same University in 1985. He also holds a PhD degree in biology (Autonomous University of Madrid, Spain). G. Kroemer is member of EMBO, German Academy of Sciences (Leopoldina), Academia Europaea and European Academy of Sciences and Arts. He received the 2006 Descartes Prize, the highest scientific distinction of the European Union, for his fundamental discoveries in the field of programmed cell death (apoptosis). He also received one of the Grands Prix from the French Academy of Sciences in 2007, as well as the Carus Medal from the German Academy of Sciences. His interests embrace the role of mitochondria in pathological cell death, the contribution of autophagy to disease processes, and the immune response to dying cancer cells.

Richard A Knight

Honorary Senior Lecturer in the Medical Molecular Biology Unit, Institute of Child Health, University College London, and member of the Apoptosis and Cancer Laboratory, Medical Research Council Toxicology Unit, Leicester, UK. Scientific interests include all aspects of cell death, especially in relation to the p53 family, the role of STAT transcription factors in cell cycle control and apoptosis and the mechanisms of cytoprotection by the urocortins, particularly in cardiovascular and neuronal pathologies.
 

Tak W Mak

Tak W. Mak is the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, and a University Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. Dr. Mak received his B.Sc. and M.Sc. degrees from the University of Wisconsin (Madison) and his Ph.D. degree from the University of Alberta. His postdoctoral work was performed at the Ontario Cancer Institute under the supervision of Dr. Ernest McCulloch. Dr. Mak's research interests center on immune cell recognition/regulation, molecular mechanisms underlying the survival and death of normal or malignant cells, as well as the role of inflammation in the progression of autoimmune disease and cancer. He is best known as the lead scientist of the group that first cloned the genes of the human T cell antigen receptor, a discovery that provided essential insights into the molecular basis of cellular immunity. In addition, Dr. Mak has devoted a large portion of his research to investigating the pathogenesis of cancer. In particular, he is interested in mechanisms of metabolic transformation in order to identify potential targets for novel cancer therapeutics.
Dr. Mak has published over 800 peer-reviewed research papers and holds many patents. His many accomplishments have been recognized by the scientific community through numerous prestigious awards and honours, such as the, Emil von Behring Prize, Gairdner International Award, King Faisal International Prize for Medicine, Sloan Prize, and Novartis Immunology Prize. He is a Fellow of the Royal Society of London, a Foreign Associate of the National Academy of Sciences (USA), an Officer of the Orders of Ontario and Canada and a Fellow of American Association for Cancer Research Academy (USA).